MOLECULAR PARTNERS AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.89 CHF | +3.87% |
|
+6.28% | +13.08% |
| Sales 2024 * | 13.86M 15.43M | Sales 2025 * | 18.66M 20.78M | Capitalization | 124M 138M |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -65.69M | Net income 2025 * | -61M -67.91M | EV / Sales 2024 * | 8.96 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.66 x |
| P/E ratio 2024 * |
-2.21
x | P/E ratio 2025 * |
-2.02
x | Employees | 168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Molecular Partners AG
More recommendations
More press releases
More news
| 1 day | +3.87% | ||
| 1 week | +6.28% | ||
| Current month | +14.41% | ||
| 1 month | +20.25% | ||
| 3 months | +5.56% | ||
| 6 months | +3.32% | ||
| Current year | +13.08% |
1 week
3.45
3.94
1 month
3.204.25
Current year
3.114.57
1 year
3.046.15
3 years
3.0428.90
5 years
3.0428.90
10 years
3.0438.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 52 | 04-11-22 | |
Patrick Amstutz
FOU | Founder | 49 | 04-11-22 |
Michael Pitzner
CMP | Compliance Officer | - | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Burns
CHM | Chairman | 76 | 17-10-30 |
Steven Holtzman
BRD | Director/Board Member | 70 | 14-09-18 |
Vito Palombella
BRD | Director/Board Member | 61 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 3.89 | +3.87% | 350 |
| 24-06-07 | 3.745 | -0.13% | 10,007 |
| 24-06-06 | 3.75 | +2.18% | 14,929 |
| 24-06-05 | 3.67 | +0.41% | 26,308 |
| 24-06-04 | 3.655 | -0.14% | 53,074 |
Delayed Quote Swiss Exchange, June 10, 2024 at 03:01 am EDT
More quotes
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.745
CHF
Average target price
9.35
CHF
Spread / Average Target
+149.67%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +13.08% | 139M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +2.50% | 22.78B | |
| -10.95% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- MOLN Stock
